This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kawakami, K. Articles by Puri, R. K. Search for Related Content PubMed PubMed Citation Articles by Kawakami, K. Articles by Puri, R. K.

Characterization of a Novel Human Tumor Antigen Interleukin-13 Receptor 2 Chain

¹ Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration; ² Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland; and ³ Department of Advanced Clinical Science and Therapeutics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

Requests for reprints: Koji Kawakami, Department of Advanced Clinical Science and Therapeutics, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Phone: 81-3-3815-5411 ext. 35642; Fax: 81-3-5800-9182; E-mail: kawakami-k{at}umin.ac.jp.

The interleukin (IL)-13 receptor 2 (IL-13R2) chain is a primary binding and internalization subunit for a Th2-derived immune regulatory cytokine, IL-13. Although extremely high levels of IL-13R2 chain are expressed on a variety of human tumor cells and specimens, its precise role in tumor immunology has not been defined. To investigate the role of IL-13R2 in tumor immunity, we used D5 melanoma cells stably transfected with the human IL-13R2 gene (D52) to assess the effect of an IL-13R2 DNA vaccine in immunocompetent animals. Prophylactic immunization of mice with the IL-13R2 DNA vaccine resulted in protection against D52 tumor development. In vivo depletion experiments in C57BL/6 and RAG-2 knockout mice indicated that both T and B cells, but not natural killer cells, were required for the tumor protection. In addition, antibody induced by the IL-13R2 DNA vaccine showed a modest but significant inhibitory effect on D52 cells in vitro, suggesting that the antibody is biologically functional. The IL-13R2 DNA vaccine also exhibited antitumor activity against established D52 tumors in mice. Histologic analysis of regressing tumors identified infiltration of CD4⁺ and CD8⁺ T cells and the expression of CXCL9 chemokine in tumors. Taken together, our results identify the human IL-13R2 chain as a novel tumor rejection antigen. (Cancer Res 2006; 66(8): 4434-42)

This article has been cited by other articles:

				Q. Li, S. Teitz-Tennenbaum, E. J. Donald, M. Li, and A. E. Chang In Vivo Sensitized and In Vitro Activated B Cells Mediate Tumor Regression in Cancer Adoptive Immunotherapy J. Immunol., September 1, 2009; 183(5): 3195 - 3203. [Abstract] [Full Text] [PDF]

				B. H. Joshi, P. Leland, A. Calvo, J. E. Green, and R. K. Puri Human Adrenomedullin Up-regulates Interleukin-13 Receptor {alpha}2 Chain in Prostate Cancer In vitro and In vivo: A Novel Approach to Sensitize Prostate Cancer to Anticancer Therapy Cancer Res., November 15, 2008; 68(22): 9311 - 9317. [Abstract] [Full Text] [PDF]

				Y. Zhao, D. He, J. Zhao, L. Wang, A. R. Leff, E. Wm. Spannhake, S. Georas, and V. Natarajan Lysophosphatidic Acid Induces Interleukin-13 (IL-13) Receptor {alpha}2 Expression and Inhibits IL-13 Signaling in Primary Human Bronchial Epithelial Cells J. Biol. Chem., April 6, 2007; 282(14): 10172 - 10179. [Abstract] [Full Text] [PDF]

				K. Kawakami, M. Terabe, M. Kioi, J. A. Berzofsky, and R. K. Puri Intratumoral Therapy with IL13-PE38 Results in Effective CTL-Mediated Suppression of IL-13R{alpha}2-Expressing Contralateral Tumors Clin. Cancer Res., August 1, 2006; 12(15): 4678 - 4686. [Abstract] [Full Text] [PDF]